Cyclin E correlates with manganese superoxide dismutase expression and predicts survival in early breast cancer patients receiving adjuvant epirubicin-based chemotherapy

16Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Anthracycline-based chemotherapy represents a milestone in the treatment of breast cancer. We previously demonstrated in an in vitro model that cyclin E overexpression is associated with increased expression of manganese superoxide dismutase (MnSOD) and resistance to doxorubicin. In the present study, immunohistochemical expression of cyclin E and MnSOD was evaluated in 134 early breast cancer patients receiving adjuvant epirubicin-based chemotherapy regimens containing epirubicin. Both parameters were correlated with the available clinicopathological parameters and with the outcome of patients. Overexpression of cyclin E and MnSOD was detected in 46 (34.3%) and 56 (41.8%) patients, respectively, and expression levels of the two proteins were related. Disease-free and alive patients displayed a lower mean percentage of cyclin E-expressing cells than relapsed and dead patients, respectively. Kaplan-Meier survival analysis demonstrated a significant separation between high versus low cyclin E-expressing tumors in terms of overall survival (P = 0.038 by log-rank). Similar results were obtained considering the subset of node-negative patients separately. No significant relationship with patient outcome was observed for MnSOD expression levels. At multivariate analysis cyclin E failed to demonstrate an independent prognostic value. In conclusion, the results of the present study support previous evidence that increased cyclin E expression is associated with higher MnSOD expression levels and poorer outcome, at least as evaluated in terms of overall survival. Further studies are warranted to evaluate the usefulness of cyclin E as a prognostic marker to identify breast cancer patients at higher risk of death from the disease when treated with adjuvant anthracycline-based therapy. (Cancer Sci 2009; 100: 1026-1033). © 2009 Japanese Cancer Association.

References Powered by Scopus

Cancer statistics, 2008

10420Citations
1438Readers

This article is free to access.

Get full text

This article is free to access.

Cited by Powered by Scopus

This article is free to access.

80Citations
26Readers

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Sgambato, A., Camerini, A., Collecchi, P., Graziani, C., Bevilacqua, G., Capodanno, A., … Amoroso, D. (2009). Cyclin E correlates with manganese superoxide dismutase expression and predicts survival in early breast cancer patients receiving adjuvant epirubicin-based chemotherapy. Cancer Science, 100(6), 1026–1033. https://doi.org/10.1111/j.1349-7006.2009.01141.x

Readers over time

‘11‘15‘17‘18‘19‘20‘2200.751.52.253

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 2

40%

Professor / Associate Prof. 1

20%

Lecturer / Post doc 1

20%

Researcher 1

20%

Readers' Discipline

Tooltip

Medicine and Dentistry 5

56%

Agricultural and Biological Sciences 2

22%

Business, Management and Accounting 1

11%

Sports and Recreations 1

11%

Save time finding and organizing research with Mendeley

Sign up for free
0